A single-nucleotide polymorphism as a predictive marker candidate for platinum-based chemotherapy

被引：0
|
作者：
Mori, Takahiro [1 ,2 ,3 ]
Nagasaki, Masao [2 ]
Ueno, Kazuko [3 ]
机构：
[1] Okinawa Chubu Hosp, Dept Med Oncol, Uruma, Okinawa, Japan
[2] Kyushu Univ, Med Inst Bioreg, Div Biomed Inform Anal, Fukuoka, Japan
[3] Natl Ctr Glob Hlth Med, Gen Med Sci Project, Tokyo, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3255
引用
收藏
页码：1708 / 1708
页数：1
相关论文
共 50 条
  • [41] ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas
    Laufs, Valeria
    Altieri, Barbara
    Sbiera, Silviu
    Kircher, Stefan
    Steinhauer, Sonja
    Beuschlein, Felix
    Quinkler, Marcus
    Willenberg, Holger S.
    Rosenwald, Andreas
    Fassnacht, Martin
    Ronchi, Cristina L.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2018, 178 (02) : 181 - 188
  • [42] NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer
    Konrad, Sarah M.
    Schwamborn, Kristina
    Krueger, Achim
    Honert, Katja
    Schmitt, Manfred
    Hellmann, Daniela
    Schmalfeldt, Barbara
    Meindl, Alfons
    Kiechle, Marion
    Quante, Anne S.
    Brambs, Christine
    Grill, Sabine
    Ramser, Juliane
    BIOMARKERS IN MEDICINE, 2022, 16 (14) : 1029 - 1041
  • [43] The effect of single-nucleotide polymorphism marker selection on patterns of haplotype blocks and haplotype frequency estimates
    Nothnagel, M
    Rohde, K
    AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 77 (06) : 988 - 998
  • [44] ERCC1 Codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy
    Kamikozuru, H.
    Kuramochi, H.
    Hayashi, K.
    Uchida, K.
    Yamamoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy
    Kamikozuru, Hirotaka
    Kuramochi, Hidekazu
    Hayashi, Kazuhiko
    Nakajima, Go
    Yamamoto, Masakazu
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 32 (05) : 1091 - 1096
  • [46] Avelumab after platinum-based chemotherapy
    Niegisch, G.
    Worst, T. S.
    UROLOGE, 2021, 60 (05): : 640 - 641
  • [47] The resurgence of platinum-based cancer chemotherapy
    Kelland, Lloyd
    NATURE REVIEWS CANCER, 2007, 7 (08) : 573 - 584
  • [48] Pharmacogenomics of platinum-based chemotherapy in NSCLC
    Hildebrandt, Michelle A. T.
    Gu, Jian
    Wu, Xifeng
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (07) : 745 - 755
  • [49] Peripheral neurotoxicity of platinum-based chemotherapy
    Cavaletti, Guido
    NATURE REVIEWS CANCER, 2008, 8 (01) : 72 - 72
  • [50] Peripheral neurotoxicity of platinum-based chemotherapy
    Guido Cavaletti
    Nature Reviews Cancer, 2008, 8 : 72 - 72
12345